ECM
VKTX icon

Endurant Capital Management’s Viking Therapeutics VKTX Stock Holding History

Endurant Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-442
Closed -$7.36K – 59
2023
Q1 		$7.36K Buy
+442
New +$4.57K ﹤0.01% 50

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Endurant Capital Management's VKTX Position: Q3 2023 in Review

Endurant Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 20,754 shares — an estimated $336K sold.

Endurant Capital Management first reported a position in VKTX in Q1 2018 and held it in 8 quarters. The position peaked at $4.07M in Q4 2022. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

  • Endurant Capital Management reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Endurant Capital Management sold 20,754 Viking Therapeutics shares in Q3 2023, an estimated $336K.
  • Endurant Capital Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 8 quarters.
  • Endurant Capital Management's Viking Therapeutics position peaked at $4.07M in Q4 2022.
  • 179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Endurant Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.